[F:1][C:2]1[CH:3]=[C:4]([N:14]2[CH2:18][CH:17]([CH2:19][N:20]=[N+]=[N-])[O:16][C:15]2=[O:23])[CH:5]=[CH:6][C:7]=1[N:8]1[CH:12]=[C:11]([CH3:13])[N:10]=[N:9]1>CO.C(OCC)(=O)C.[Pd]>[NH2:20][CH2:19][C@@H:17]1[O:16][C:15](=[O:23])[N:14]([C:4]2[CH:5]=[CH:6][C:7]([N:8]3[CH:12]=[C:11]([CH3:13])[N:10]=[N:9]3)=[C:2]([F:1])[CH:3]=2)[CH2:18]13-[3-Fluoro-4-(4-methyl-1,2,3-triazol-1-yl)phenyl]-5-(azidomethyl)-oxazolidin-2-one (Intermediate 17) (2.0 g, 6.30 mmol) was dissolved in methanol/ethyl acetate (50 ml, 1:1) and hydrogenated over palladium on carbon (10%, 0.2 g) at room temperature and normal pressure for 4 hours. The resulting mixture was filtered through the celite and concentrated under reduced pressure to give 1.02 g of the title compound as a solid, which was used without further purification in the next step.
Wird geladen…